SCHEMBL16180644

SCHEMBL16180644

O=Cc1c(Br)c(=O)c(OCc2ccccc2)c2n1CCN(Cc1ccc(F)c(Cl)c1)C2=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.39
CLPP Q16740 3/20 0.39
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
DRD4 P21917 1/20 0.36
SCD O00767 1/20 0.36
GRM2 Q14416 6/20 0.35
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16185235 0.86 KCNH2 (0.39) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16185202 0.86 SCD (0.39) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16180509 0.86 SCD (0.39) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16180765 0.86 SCD (0.36) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16180602 0.84 KCNH2 (0.36) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16185297 0.84 SCD (0.39) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16185206 0.83 CLPP (0.36) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16185301 0.83 SCD (0.39) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL16185210 0.83 KCNH2 (0.36) KCNH2CLPPLMNASMN1; SMN2L3MBTL1
SCHEMBL17537049 0.83 KCNH2 (0.36) KCNH2CLPPLMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2986291-B1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2020-05-27 EP disclosed
US-9493479-B2 Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-11-15 US disclosed
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-03-03 US disclosed
EP-2986291-A2 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-02-24 EP disclosed
WO-2014172188-A2 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060272-A1 4-PYRIDONE DERIVATIVE COMPOUNDS AND USES THEREOF AS HIV INTEGRASE INHIBITORS PNPO, TYMP, PDXK KCNH2 2585/4885CLPP 2603/4885LMNA 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.